FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206807960> ?p ?o ?g. }

• W3206807960 endingPage "101158" @default.
• W3206807960 startingPage "101158" @default.
• W3206807960 abstract "BackgroundTrials of the Pfizer-BioNTech BNT162b2 mRNA vaccine showed 95% efficacy in preventing symptomatic disease; however, the trials excluded immunocompromised patients (ICPs). We aim at analyzing antibody response in ICPs.MethodsA prospective cohort study was conducted at Sheba Medical Center, Israel, between January and April 2020, in 1274 participants who received the vaccine, including 1002 ICPs and 272 immunocompetent healthcare workers (HCWs). Antibodies were measured two-four weeks after vaccination by SARS-CoV-2 anti–receptor binding domain IgG antibodies (RBD IgG) and pseudo-virus neutralization assays. Multivariable logistic regression analyses were used to identify factors associated with vaccine-induced antibody response. Adverse events (AEs) were monitored.FindingsRBD-IgG antibodies were detected in 154/156 (98.7%) of patients with HIV, 75/90 (83.3%) with solid malignancies, 149/187 (79.7%) with myeloma, 83/111 (74.8%) following hematopoietic stem cell transplants, 25/36 (69.4%) following liver transplantation, 26/43 (60.5%) with myelodysplastic syndrome, 96/188 (51.0%) with chronic lymphocytic leukemia/non-Hodgkin's lymphoma, 50/110 (45.5%) following kidney transplantation, 15/80 (18.8%) following heart transplantation, and 269/272 (98.9%) in controls. There was a significant correlation r = 0.74 (95%CI 0.69,0.78) between RBD-binding IgG and neutralizing antibodies in all groups. Multivariate logistic regression analysis showed that age > 65 years (OR 0.41,95%CI 0.30,0.57) and underlying immunosuppression (OR 0.02,95%CI 0.01,0.07) were significantly associated with a non-reactive response of IgG antibodies. HIV patients showed a similar immunological response as healthy adults. The vaccine was safe without any episodes of rejection, graft-versus-host disease (GVHD) or allergy. Immunocompetent HCWs experienced significantly more AEs than ICPs.InterpretationAntibody response to the Pfizer-BioNTech vaccine was highly variable among different ICPs; thus, individual recommendations should be provided for the different immunosuppression states.FundingNone." @default.
• W3206807960 created "2021-10-25" @default.
• W3206807960 creator A5002536186 @default.
• W3206807960 creator A5007703509 @default.
• W3206807960 creator A5016110998 @default.
• W3206807960 creator A5024644388 @default.
• W3206807960 creator A5033290213 @default.
• W3206807960 creator A5035520823 @default.
• W3206807960 creator A5045152818 @default.
• W3206807960 creator A5045531308 @default.
• W3206807960 creator A5046346627 @default.
• W3206807960 creator A5046837534 @default.
• W3206807960 creator A5047023960 @default.
• W3206807960 creator A5048591272 @default.
• W3206807960 creator A5054237637 @default.
• W3206807960 creator A5054900639 @default.
• W3206807960 creator A5068865686 @default.
• W3206807960 creator A5070745060 @default.
• W3206807960 creator A5073481880 @default.
• W3206807960 creator A5080128827 @default.
• W3206807960 creator A5085626163 @default.
• W3206807960 date "2021-11-01" @default.
• W3206807960 modified "2023-10-17" @default.
• W3206807960 title "BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study" @default.
• W3206807960 cites W2160358721 @default.
• W3206807960 cites W2595163384 @default.
• W3206807960 cites W2599076725 @default.
• W3206807960 cites W2914146049 @default.
• W3206807960 cites W3006355661 @default.
• W3206807960 cites W3039409489 @default.
• W3206807960 cites W3041318796 @default.
• W3206807960 cites W3090844627 @default.
• W3206807960 cites W3092303353 @default.
• W3206807960 cites W3093367571 @default.
• W3206807960 cites W3097630077 @default.
• W3206807960 cites W3099879565 @default.
• W3206807960 cites W3107861020 @default.
• W3206807960 cites W3111255098 @default.
• W3206807960 cites W3112675846 @default.
• W3206807960 cites W3129963120 @default.
• W3206807960 cites W3133936567 @default.
• W3206807960 cites W3135260899 @default.
• W3206807960 cites W3153040293 @default.
• W3206807960 cites W3154374447 @default.
• W3206807960 cites W3154381950 @default.
• W3206807960 cites W3155756133 @default.
• W3206807960 cites W3156866359 @default.
• W3206807960 cites W3157860346 @default.
• W3206807960 cites W3162395942 @default.
• W3206807960 cites W3164768289 @default.
• W3206807960 cites W3175432865 @default.
• W3206807960 cites W3176479223 @default.
• W3206807960 cites W3183662884 @default.
• W3206807960 cites W4292229870 @default.
• W3206807960 doi "https://doi.org/10.1016/j.eclinm.2021.101158" @default.
• W3206807960 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8520708" @default.
• W3206807960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34693234" @default.
• W3206807960 hasPublicationYear "2021" @default.
• W3206807960 type Work @default.
• W3206807960 sameAs 3206807960 @default.
• W3206807960 citedByCount "61" @default.
• W3206807960 countsByYear W32068079602021 @default.
• W3206807960 countsByYear W32068079602022 @default.
• W3206807960 countsByYear W32068079602023 @default.
• W3206807960 crossrefType "journal-article" @default.
• W3206807960 hasAuthorship W3206807960A5002536186 @default.
• W3206807960 hasAuthorship W3206807960A5007703509 @default.
• W3206807960 hasAuthorship W3206807960A5016110998 @default.
• W3206807960 hasAuthorship W3206807960A5024644388 @default.
• W3206807960 hasAuthorship W3206807960A5033290213 @default.
• W3206807960 hasAuthorship W3206807960A5035520823 @default.
• W3206807960 hasAuthorship W3206807960A5045152818 @default.
• W3206807960 hasAuthorship W3206807960A5045531308 @default.
• W3206807960 hasAuthorship W3206807960A5046346627 @default.
• W3206807960 hasAuthorship W3206807960A5046837534 @default.
• W3206807960 hasAuthorship W3206807960A5047023960 @default.
• W3206807960 hasAuthorship W3206807960A5048591272 @default.
• W3206807960 hasAuthorship W3206807960A5054237637 @default.
• W3206807960 hasAuthorship W3206807960A5054900639 @default.
• W3206807960 hasAuthorship W3206807960A5068865686 @default.
• W3206807960 hasAuthorship W3206807960A5070745060 @default.
• W3206807960 hasAuthorship W3206807960A5073481880 @default.
• W3206807960 hasAuthorship W3206807960A5080128827 @default.
• W3206807960 hasAuthorship W3206807960A5085626163 @default.
• W3206807960 hasBestOaLocation W32068079601 @default.
• W3206807960 hasConcept C126322002 @default.
• W3206807960 hasConcept C151956035 @default.
• W3206807960 hasConcept C159654299 @default.
• W3206807960 hasConcept C188816634 @default.
• W3206807960 hasConcept C197934379 @default.
• W3206807960 hasConcept C203014093 @default.
• W3206807960 hasConcept C22070199 @default.
• W3206807960 hasConcept C2777408962 @default.
• W3206807960 hasConcept C2780252810 @default.
• W3206807960 hasConcept C2911091166 @default.
• W3206807960 hasConcept C71924100 @default.
• W3206807960 hasConcept C72563966 @default.
• W3206807960 hasConceptScore W3206807960C126322002 @default.

• next